Claims
- 1. A method of preventing or treating carnitine deficiency in chronic uremic patients undergoing periodic dialysis comprising administering to the patient at the conclusion of dialysis an effective amount of L-carnitine or a pharmaceutically acceptable salt thereof.
- 2. The method of claim 1, wherein administration is by the intravenous route.
- 3. The method of claim 1, wherein administration is by the peritoneal route.
- 4. The method of claim 1, wherein from about 10 to about 20 mg/kg body weight of carnitine, calculated as L-carnitine, is administered into a venous return line at the end of a dialysis session.
- 5. The method of claim 1, wherein L-carnitine fumarate is administered.
- 6. A method of preventing or treating carnitine deficiency in chronic uremic patients undergoing periodic dialysis comprising administering to the patient at the conclusion of dialysis an effective amount of L-carnitine fumarate.
- 7. The method of claim 6, wherein administration is by the intravenous route.
- 8. The method of claim 6, wherein administration is by the peritoneal route.
- 9. The method of claim 6, wherein from about 10 to about 20 mg/kg body weight of carnitine, calculated as L-carnitine, is administered into a venous return line at the end of a dialysis session.
- 10. A method of preventing carnitine deficiency in end stage uremic patients undergoing periodic dialysis over an extended period of time, said method comprising administering to the patent at the conclusion of each dialysis session an effective amount of L-carnitine or a pharmaceutically acceptable salt thereof.
- 11. The method of claim 10, wherein administration is by the intravenous route.
- 12. The method of claim 10, wherein administration is by the peritoneal route.
- 13. The method of claim 10, wherein from about 10 to about 20 mg/kg body weight of carnitine, calculated as L-carnitine, is administered into a venous return line at the end of a dialysis session.
- 14. The method of claim 10, wherein L-carnitine fumarate is administered.
Parent Case Info
This application claims the benefit of U.S. Provisional Application No. 60/176,629 and 60/186,328, filed Jan. 19, 2000 and Mar. 2, 2001, respectively the entire content of which is hereby incorporated by reference in this application.
US Referenced Citations (4)
Number |
Name |
Date |
Kind |
4272549 |
Cavazza |
Jun 1981 |
A |
4602039 |
Cavazza |
Jul 1986 |
A |
6051608 |
Santaniello et al. |
Apr 2000 |
A |
6245378 |
Cavazza |
Jun 2001 |
B1 |
Non-Patent Literature Citations (3)
Entry |
Ahmad et al Kidney International, vol. 36, Suppl. 27 (1989), pp. S-243-S-246 Fatty Acid abnormalitites in hemodialysis patients: Effect of L-carnitine administration. |
Golfer et al Kidney International vol. 38 (1990) pp. 904-911 Multicenter trial of L-carnitine in maintenance hemodialysis patients. I. Carnitine concentrations and lipid effects. |
Ahmad et al Kidney International vol. 38 (1990) pp. 912-918 Multicenter trial of L-carnitine in maintenance hemodialysis patients. II. Clinical and biochemical effects. |
Provisional Applications (2)
|
Number |
Date |
Country |
|
60/176629 |
Jan 2000 |
US |
|
60/186328 |
Mar 2001 |
US |